Denali Therapeutics Inc. (DNLI) NASDAQ

20.71

+0.14(+0.68%)

Updated at March 17 04:00PM

Currency In USD

Key Executives

Name	Title	Pay	Year Born
Ryan J. Watts	Co-Founder, President, Chief Executive Officer & Director	1.33M	1976
Alexander O. Schuth	Co-Founder, Chief Financial Officer, Chief Operating Officer & Secretary	886,816	1973
Dana Andersen	Chief Technical and Manufacturing Officer	0	N/A
Chris Walsh	General Counsel	0	N/A
Joe Lewcock	Chief Scientific Officer	0	N/A
Peter Chin	Acting Chief Medical Officer & Head of Development	0	N/A
Cindy Dunkle	Chief People Officer	0	N/A
Katie Peng	Chief Commercial Officer	0	1971

Name

Title

Pay

Year Born

Ryan J. Watts

Co-Founder, President, Chief Executive Officer & Director

1.33M

1976

Alexander O. Schuth

Co-Founder, Chief Financial Officer, Chief Operating Officer & Secretary

886,816

1973

Dana Andersen

Chief Technical and Manufacturing Officer

N/A

Chris Walsh

General Counsel

N/A

Joe Lewcock

Chief Scientific Officer

N/A

Peter Chin

Acting Chief Medical Officer & Head of Development

N/A

Cindy Dunkle

Chief People Officer

N/A

Katie Peng

Chief Commercial Officer

1971

Description

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease. The company also develops DNL310 that is in Phase I/II clinical trials for the treatment of hunter syndrome; DNL343, which is in phase 1 clinical trial the treatment of amyotrophic lateral sclerosis (ALS); AR443820/DNL788 completed a phase I clinical trial for the treatment of ALS, multiple sclerosis (MS), and Alzheimer's disease; and SAR443122/DNL758, which is in phase II clinical trial for the treatment of cutaneous lupus erythematosus. It has collaboration agreement with Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, and Centogene; and a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG. to develop antisense therapies in the field of neurodegenerative diseases. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.